Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
about
Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates.What is hidden in the pannexin treasure trove: the sneak peek and the guessworkGlioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response.The role of gap junction channels during physiologic and pathologic conditions of the human central nervous systemGene therapy and targeted toxins for glioma.Development and application of replication-incompetent HSV-1-based vectors.Herpes simplex virus 1 (HSV-1) for cancer treatment.Stereotactic radiosurgery: adjacent tissue injury and response after high-dose single fraction radiation. Part II: Strategies for therapeutic enhancement, brain injury mitigation, and brain injury repair.Molecular approaches to sarcoma therapy.HSV Recombinant Vectors for Gene Therapy.Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.Herpes simplex viral vectors: late bloomers with big potential.Endothelial differentiation of adipose tissue-derived mesenchymal stromal cells in glioma tumors: implications for cell-based therapy.Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification.Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.Bystander-mediated regression of murine neuroblastoma via retroviral transfer of the HSV-TK gene.Disruption of gap junctions attenuates aminoglycoside-elicited renal tubular cell injury.Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery.Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector.Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir.Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat.Human adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander effect: a model based on bioluminescence imaging.Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy.HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.The Novel Roles of Connexin Channels and Tunneling Nanotubes in Cancer Pathogenesis.Gene therapy and targeted toxins for glioma
P2860
Q28210728-1F58E3FC-4F93-4F9F-9173-2245D25B4839Q28264681-2563DBAD-2445-491E-8807-D79C79AD78F8Q34243638-33F19E8E-8051-49E8-BE9C-2FF2B8D54F44Q34262821-6B58E4E4-FEA2-4132-9CEA-89843E0024D5Q35118933-E80C4957-8680-46A7-8E66-F236547ACA84Q36288938-04C464C4-BE53-455B-88F8-251E6B473F1FQ36444443-FC7C929E-8196-4669-986A-E8A760D197EDQ36802285-0337CB0F-49A8-47B9-87DF-816C5353E168Q37180948-34B6D5CA-B7C6-4BB5-AEAA-DE3875E84915Q37787777-0E607026-6C85-4C0E-9873-8411BD699EA4Q37818222-0CE95C0C-449A-4EEB-A3E5-4588377178C2Q38185694-2B2509C2-32FC-42AD-8E01-1EFE4FA9567BQ39140400-699D671A-A6CB-4EA7-845D-BBD00E851ABDQ39756417-B7C739CF-2700-400C-8931-FCCBE30448F0Q40373406-9F90C2DD-5B88-4619-9A80-21F0C44CC88DQ40589509-8E4EB5CC-7120-4C94-A821-31276C5AEFC6Q42407358-E4D498B4-DCA3-4095-8233-7EBD5F33AAC2Q43583239-3EF5D444-75F6-473C-B296-9B72F2F68539Q43890874-0D9397B7-1282-41C8-897B-29CCBCCDC738Q43934769-267842D9-4723-4DB5-92EE-E4B2FA6A5FD4Q44233116-86D5AFAE-F112-4E24-9B29-E9CB759CF310Q44253862-ADD4C5C0-65C7-4DF5-975E-CD5BC0BC231BQ44793632-C347A7D1-BF5B-4631-A0A0-A0E4B911B000Q45251720-FF675F57-A719-4E25-BFBF-6637BB6E2E95Q45857430-406E6651-608B-467E-ACA9-F7A65B18981FQ45871057-8B5AD786-90E5-46C7-8161-54533704929EQ52563269-A8850720-D01B-449E-9223-58D85ED32B08Q57006162-CEFDB176-4F59-4D08-92A0-C71E68B403B8
P2860
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@en
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@nl
type
label
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@en
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@nl
prefLabel
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@en
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@nl
P2093
P356
P1433
P1476
Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
@en
P2093
P356
10.1006/MTHE.1999.0008
P577
2000-01-01T00:00:00Z